173 related articles for article (PubMed ID: 32051231)
1. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.
Wang J; McGrail DJ; Bhupal PK; Zhang W; Lin KY; Ku YH; Lin T; Wu H; Tsai KC; Li K; Peng CY; Finegold MJ; Lin SY; Tsai RYL
Mol Cancer Res; 2020 May; 18(5):723-734. PubMed ID: 32051231
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
3. Nucleostemin Knockdown Sensitizes Hepatocellular Carcinoma Cells to Ultraviolet and Serum Starvation-Induced Apoptosis.
Yuan F; Cheng Q; Li G; Tong T
PLoS One; 2015; 10(10):e0141678. PubMed ID: 26517370
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
6. Nucleostemin/GNL3 promotes nucleolar polyubiquitylation of p27
Hu B; Hua L; Ni W; Wu M; Yan D; Chen Y; Lu C; Chen B; Wan C
Cancer Lett; 2017 Mar; 388():220-229. PubMed ID: 27998760
[TBL] [Abstract][Full Text] [Related]
7. Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression.
Lin T; Lin TC; McGrail DJ; Bhupal PK; Ku YH; Zhang W; Meng L; Lin SY; Peng G; Tsai RYL
Oncogene; 2019 May; 38(20):3919-3931. PubMed ID: 30692636
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
[TBL] [Abstract][Full Text] [Related]
9. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
[TBL] [Abstract][Full Text] [Related]
10. RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway.
Li H; Zhuang H; Gu T; Li G; Jiang Y; Xu S; Zhou Q
Funct Integr Genomics; 2023 Apr; 23(2):128. PubMed ID: 37071224
[TBL] [Abstract][Full Text] [Related]
11. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
13. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
16. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
17. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.
Xu JH; Guan YJ; Qiu ZD; Zhang X; Zi LL; Zhou Y; Chen C; Yu J; Zhang YC; Wang WX
Oxid Med Cell Longev; 2021; 2021():6485871. PubMed ID: 34795841
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
20. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]